Returning Research Results that Indicate Risk of Alzheimer Disease to Healthy Participants in Longitudinal Studies
Returning Research Results that Indicate Risk of Alzheimer Disease to Healthy Participants in Longitudinal Studies
批准号:
10557822
负责人:
Sarah Hartz
金额:
$70.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-02-01 至 2025-01-31
关键词:
African AmericanAgeAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease riskAmyloidBiological MarkersBrainClinicalClinical TrialsClinical Trials DesignCognitiveCommunicationConsentDataDementiaDevelopmentDiseaseEarly intervention trialsEducational MaterialsElderlyEnrollmentEthicsEvaluationEventFoundationsFrightFutureGeneticGenotypeGoalsHealthcareIndividualInformed ConsentInterviewKnowledgeLongitudinal StudiesLongitudinal cohortMagnetic Resonance ImagingMethodologyMethodsOutcomeParticipantPatient RecruitmentsPatientsPersonsPositron-Emission TomographyProcessRaceRandomizedRecommendationRegretsReportingResearchResourcesRiskRisk AdjustmentScanningSigns and SymptomsSolidTest ResultTestingThinkingTraining ActivityUnited States National Academy of SciencesUniversitiesWashingtonarmbehavior changecognitive changecognitive testingcohortdesignfuture implementationhealth care service utilizationhealthy agingimplementation scienceinnovationinterestneuroimagingpre-clinicalprimary outcomepsychosocialracial differencerandomized, clinical trialsresearch studysecondary analysissexsuccesstrial enrollmenttwo-arm studyuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
This project will determine the impact of returning research results that indicate 5-year risk of developing
Alzheimer Disease (AD) to healthy older adults enrolled in a longitudinal cohort of aging. Returning research
results that indicate risk of AD is controversial for ethical and scientific reasons. Ethical concerns relate to the
potential harms of informing individuals their risk of a highly feared untreatable disease. Scientific concerns
relate to the potential change in cognitive test results due to knowing one’s risk of AD, potentially
compromising the scientific integrity of research studies that follow cognitive outcomes. However, participants
in longitudinal studies of AD increasingly ask for their research results to understand their AD risk. Returning
research results to those who wish to receive them respects autonomy and recognizes participant contributions
to research. Evidence is needed to determine the impact of returning research results on psychosocial and
cognitive outcomes to responsibly design future studies in AD.
A randomized delayed-start clinical trial will evaluate the impact of returning research results to participants in
longitudinal studies of aging. All participants of a longitudinal cohort of aging will be offered the option to
receive research results from a recent PET amyloid scan, MRI, and APOE genotype, presented as a
synthesized 5-year risk of developing AD. All consenting participants will be randomized to either receiving
their research results within 2 weeks or after 1 year. Those who choose to receive results will be followed for
up to 24 months to determine the impact of receiving results on cognitive and psychosocial outcomes. Aim 1
will quantitatively and qualitatively explore the decision to receive results and reasons for declining or choosing
to receive results. Aim 2 will use quantitative and qualitative analyses to determine the effect of returning
research results on 1-year cognitive and psychosocial outcomes. Aim 3 will assess feasibility, acceptability,
and resource requirements of the return of results process and develop educational materials and a training
module for future implementation.
Laying the foundation for widespread return of research results, this is the first systematic and comprehensive
approach to returning research results in cognitively normal persons engaged in biomarker studies of AD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating the longitudinal relationship between alcohol use, neurophysiological functioning, and Alzheimer disease biomarkers in the Collaborative Study on the Genetics of Alcoholism
-
批准号:10660983
-
项目类别:
-
资助金额:$39.38万
-
财政年份:2020
-
负责人:Sarah Hartz
-
依托单位:
Investigating the longitudinal relationship between alcohol use, neurophysiological functioning, and Alzheimer disease biomarkers in the Collaborative Study on the Genetics of Alcoholism
-
批准号:10266834
-
项目类别:
-
资助金额:$39.38万
-
财政年份:2020
-
负责人:Sarah Hartz
-
依托单位:
Investigating the longitudinal relationship between alcohol use, neurophysiological functioning, and Alzheimer disease biomarkers in the Collaborative Study on the Genetics of Alcoholism
-
批准号:10442692
-
项目类别:
-
资助金额:$39.38万
-
财政年份:2020
-
负责人:Sarah Hartz
-
依托单位:
Returning Research Results that Indicate Risk of Alzheimer Disease to Healthy Participants in Longitudinal Studies
-
批准号:10528160
-
项目类别:
-
资助金额:$39.36万
-
财政年份:2020
-
负责人:Sarah Hartz
-
依托单位:
THE SHARED GENETICS OF ALCOHOL-RELATED DISORDERS AND SCHIZOPHRENIA
-
批准号:9243628
-
项目类别:
-
资助金额:$19.5万
-
财政年份:2017
-
负责人:Sarah Hartz
-
依托单位:
THE SHARED GENETICS OF ALCOHOL-RELATED DISORDERS AND SCHIZOPHRENIA
-
批准号:9462002
-
项目类别:
-
资助金额:$22.16万
-
财政年份:2017
-
负责人:Sarah Hartz
-
依托单位:
Novel Use of Gwas for Improved Understanding of Nicotine Dependence
-
批准号:8655533
-
项目类别:
-
资助金额:$13.75万
-
财政年份:2012
-
负责人:Sarah Hartz
-
依托单位:
Novel Use of Gwas for Improved Understanding of Nicotine Dependence
-
批准号:8224503
-
项目类别:
-
资助金额:$13.75万
-
财政年份:2012
-
负责人:Sarah Hartz
-
依托单位:
Novel Use of Gwas for Improved Understanding of Nicotine Dependence
-
批准号:8469460
-
项目类别:
-
资助金额:$13.75万
-
财政年份:2012
-
负责人:Sarah Hartz
-
依托单位:
Novel Use of Gwas for Improved Understanding of Nicotine Dependence
-
批准号:9043013
-
项目类别:
-
资助金额:$13.75万
-
财政年份:2012
-
负责人:Sarah Hartz
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: